Vanguard Global Advisers
FBLG icon

Vanguard Global Advisers’s FibroBiologics FBLG Stock Holding History

Vanguard Global Advisers’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-536
Closed -$708 – 3747
2026
Q1 		$708 Buy
+536
New +$3.19K ﹤0.01% 3647

Other funds holding FBLG

CFP
Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return
FEG
Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Vanguard Global Advisers's FBLG Position: Q2 2026 in Review

Vanguard Global Advisers sold out of FibroBiologics (FBLG) in Q2 2026, closing a stake of 536 shares — an estimated $708 sold.

Vanguard Global Advisers first reported a position in FBLG in Q1 2026 and held it in 1 quarter. The position peaked at $708 in Q1 2026. 16 funds tracked by Wall St. Rank hold FBLG as of Q2 2026.

  • Vanguard Global Advisers reported no remaining FibroBiologics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 536 FibroBiologics shares in Q2 2026, an estimated $708.
  • Vanguard Global Advisers first reported a position in FibroBiologics in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's FibroBiologics position peaked at $708 in Q1 2026.
  • 16 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.